论文部分内容阅读
乙吗噻嗪(Ethmozin)是苏联合成的一种抗心律失常药物。早年的药理和临床研究表明,它可能是控制房性和室性心律失常的有效药物。此药对离体犬非缺血浦顷野纤维的电生理作用类似利多卡因,抑制0位相最大除极速率和缩短动作电位时限。同利多卡因不同的是,它不影响浦顷野纤维舒张期第4位相自发除极。然而,在缺血浦顷野纤维,则降低第4位相除极坡度。乙吗噻嗪能有效地抑制清醒狗结扎冠状动脉24小时后诱发的心律失常,且在相应剂量下远较奎尼丁有效。本文报道在美国短期试用此药的临床经验。方法:男16例,女1例,年龄31～68岁,均为临床稳定病例,在最近三个月无急性梗塞,具有不危及生命的室性及或房性心律失常。其中14例患有室性早搏,每小时平均48～1801次;8例患有房性早搏,每小时平均69～693次。17例中7例为冠
Ethmozin is an anti-arrhythmic drug synthesized in the Soviet Union. Early pharmacological and clinical studies have shown that it may be an effective drug to control atrial and ventricular arrhythmias. The drug on isolated dog non-ischemic purpura fibers similar to the electrophysiological role of lidocaine, inhibition of 0 phase maximum depolarization rate and shorten the action potential time limit. Unlike lidocaine, it does not affect spontaneous depolarization of the 4th phase of the diastolic phase of Pu arena fiber. However, in Isuzu Porphyrin fibers, the 4th place is divided by the polar gradient. Bothiazide can effectively inhibit arrhythmia induced by awake dogs after coronary artery ligation for 24 hours and is far more effective than quinidine at the corresponding doses. This article reports the clinical trial of the drug in the United States in the near term. Methods: There were 16 males and 1 females aged from 31 to 68 years old, all of whom were clinically stable cases with no acute infarction in the last three months, with non-life threatening ventricular and atrial arrhythmias. Among them, 14 patients had premature ventricular contractions, with an average of 48 ~ 1801 times per hour; 8 patients had atrial premature beats, with an average of 69 ~ 693 times per hour. Seven of 17 cases were crowned